CannaWize Editorial
The Research Desk
Clinical trials, systematic reviews, public-health evidence, and the limits that headlines leave out.
Research coverage at CannaWize begins with the exact intervention. Flower, a standardized oral spray, purified CBD, synthetic cannabinoids, and a retail edible cannot be treated as one product. The dose, route, study population, comparison group, and length of follow-up determine what a result can support.
Our reviews look for the size of a benefit, not only whether a result reached statistical significance. They also track adverse effects, withdrawals, uncertainty, and conflicts between studies. Promising evidence is reported as promising—not promoted into a cure.
Latest Research Articles
Updated as evidence, products, and rules change.
Can Cannabis Ease Opioid Withdrawal? The Evidence Is Early and Uneven
A review of cannabis and opioid withdrawal research, including a 2026 proof-of-concept study, observational findings, THC risks, and evidence from medication treatment.
ResearchCannabinoids for Dementia Agitation: A Signal with Serious Limits
What randomized trials and 2026 meta-analyses say about cannabinoids for agitation in dementia, including effect signals, sedation, heterogeneity, and caregiver questions.
ResearchCannabis for Restless Legs Syndrome: One Small Trial, Many Open Questions
A 2026 open-label trial reported improvement in restless legs syndrome, mostly among people with multiple sclerosis. Here is why the result is promising but not conclusive.
ResearchDo THC Beverages Reduce Alcohol Use? Two Studies Point to a Maybe
A 2026 survey and randomized laboratory study found signs of reduced alcohol use after cannabis beverages or THC, but neither makes THC an alcohol treatment.
ResearchWhy Cancer Survivors Use Cannabis—And What Their Doctors Need to Know
A national survey of cancer survivors found cannabis use for sleep, pain, stress, nausea, and mood. Here is what the survey proves, what it cannot, and why disclosure matters.
ResearchCannabis and Anxiety: Why Dose and Product Matter
A plain-language review of cannabis and anxiety research, including the different evidence for THC and CBD, dose-related risk, and the limits of current trials.
ResearchCannabis and Driving: Impairment Is Not a THC Number
What driving research says about cannabis impairment, why blood THC is difficult to interpret, and how to make a safer transportation plan.
ResearchCannabis and Medication Interactions: A Practical Checklist
How CBD and THC can interact with medicines, why dose and liver metabolism matter, and what information to bring to a pharmacist or clinician.
ResearchCannabis and Sleep: What Research Can—And Cannot—Say
A source-led review of cannabis, CBD, and sleep research, including short-term sedation, insomnia evidence, tolerance, next-day effects, and study limitations.
ResearchCannabis for Chronic Pain: What the 2025 Evidence Shows
A plain-language review of the 2025 AHRQ cannabis and chronic pain evidence, including likely benefits, limits, side effects, and unanswered questions.